Versor Investments LP Lowers Position in Pfizer Inc. $PFE

Key Points

• Versor Investments LP has significantly reduced its stake in Pfizer Inc. by 61.4%, holding 8,300 shares worth $210,000 after selling 13,200 shares in the first quarter.
• Several institutional investors, including Summit Securities Group and Affinity Investment Advisors, have increased their positions in Pfizer, indicating a mixed sentiment among hedge funds regarding the stock.
• Nonetheless, Pfizer recently announced a quarterly dividend of $0.43, contributing to an annualized dividend yield of 6.7%.

Versor Investments LP reduced its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 61.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,300 shares of the biopharmaceutical company's stock after selling 13,200 shares during the quarter. Versor Investments LP's holdings in Pfizer were worth $210,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. Summit Securities Group LLC increased its position in shares of Pfizer by 5.0% during the 1st quarter. Summit Securities Group LLC now owns 25,000 shares of the biopharmaceutical company's stock valued at $634,000 after purchasing an additional 1,200 shares during the last quarter. Freestone Capital Holdings LLC increased its position in shares of Pfizer by 2.8% during the 1st quarter. Freestone Capital Holdings LLC now owns 132,187 shares of the biopharmaceutical company's stock valued at $3,350,000 after purchasing an additional 3,558 shares during the last quarter. Affinity Investment Advisors LLC increased its position in shares of Pfizer by 25.5% during the 1st quarter. Affinity Investment Advisors LLC now owns 57,326 shares of the biopharmaceutical company's stock valued at $1,453,000 after purchasing an additional 11,650 shares during the last quarter. CacheTech Inc. increased its position in shares of Pfizer by 10.6% during the 1st quarter. CacheTech Inc. now owns 25,402 shares of the biopharmaceutical company's stock valued at $644,000 after purchasing an additional 2,426 shares during the last quarter. Finally, Algert Global LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at $2,646,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.3%

PFE stock opened at $25.8250 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $146.83 billion, a price-to-earnings ratio of 13.74, a PEG ratio of 0.92 and a beta of 0.52. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock has a fifty day moving average of $24.70 and a 200-day moving average of $24.42.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the company earned $0.60 EPS. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PFE. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Jefferies Financial Group raised their target price on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. The Goldman Sachs Group raised their target price on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, HSBC decreased their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.